172 related articles for article (PubMed ID: 20058135)
21. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Takeda M; Okamoto I; Hirabayashi N; Kitano M; Nakagawa K
Lung Cancer; 2011 Jul; 73(1):103-9. PubMed ID: 21111509
[TBL] [Abstract][Full Text] [Related]
22. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
Kai K; Endo Y; Yoshida K; Morikawa T; Nobuhisa T; Watanabe T; Matsumoto Y; Yamada T; Doi Y; Nakashima A; Nagahiro W; Ishizuka S; Sato S; Nakashima A; Nabeyama A
Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
[TBL] [Abstract][Full Text] [Related]
23. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
24. Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Miyamoto H; Morio A; Izumi H; Yamazaki A; Wang Z; Futagawa T; Sonobe S
Anticancer Res; 2003; 23(5b):4153-6. PubMed ID: 14666617
[TBL] [Abstract][Full Text] [Related]
25. Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Miyoshi T; Kondo K; Fujino H; Takahashi Y; Sawada N; Sakiyama S; Tsuyuguchi M; Kimura S; Sumitomo M; Monden Y
Anticancer Res; 2005; 25(2A):923-30. PubMed ID: 15868929
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
27. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
28. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Schmoll HJ
Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
[TBL] [Abstract][Full Text] [Related]
29. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
[TBL] [Abstract][Full Text] [Related]
31. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
32. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
Minsky BD
Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
[TBL] [Abstract][Full Text] [Related]
33. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
[TBL] [Abstract][Full Text] [Related]
34. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Ito Y; Nakanishi H; Kodera Y; Hirai T; Nakao A; Kato T
Cancer Sci; 2010 Aug; 101(8):1853-60. PubMed ID: 20500514
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
37. UFT: biochemical modulation for 5-fluorouracil (5-FU).
Taguchi T
Chin Med J (Engl); 1997 Apr; 110(4):294-6. PubMed ID: 9594232
[No Abstract] [Full Text] [Related]
38. Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Ishizuka M; Kubota K; Nemoto T; Shimoda M; Kato M; Iso Y; Tago K
Asian J Surg; 2016 Jul; 39(3):149-54. PubMed ID: 26123137
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer.
Takiguchi N; Koda K; Ooshima H; Oda K; Suzuki H; Ishii R; Miyazaki M
Anticancer Drugs; 2002 Apr; 13(4):411-6. PubMed ID: 11984087
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]